Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-08

Clinical Trial Update: Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 2]

View source ↗

Summary

Phase 2 trial studying IFX-1 for hidradenitis suppurativa has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IFX-1 (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Hidradenitis Suppurativa (HS) | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08